伏立诺他|T1583|TargetMol

Vorinostat
149647-78-9

￥326 50mg 起订

￥817 200mg 起订

￥1223 500mg 起订

上海更新日期：2024-12-02

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 伏立诺他

英文名称：: Vorinostat

CAS号：: 149647-78-9

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.93%

产品类别：: 抑制剂

货号：: T1583

Product Introduction

Bioactivity

名称	Vorinostat
描述	Vorinostat (SAHA) is a pan-histone deacetylase (HDAC) inhibitor (IC50=10 nM) with inhibitory activity against HDAC1/2/3/6/7/11. Vorinostat has antitumor activity, induces cell differentiation, blocks the cell cycle and induces apoptosis.
细胞实验	Cells were plated onto 100-mm tissue culture plates at a density of 2 × 10^6 for 48 h and then treated with SAHA or equal concentrations of the vehicle. For longer drug exposure times, medium with drug or vehicle were exchanged every 48 h. For wash-out experiments, cells were treated with SAHA daily for 60–72 h (drug and medium were exchanged at 48 h), then SAHA was washed out and replaced with 10% FCS containing DMEM [3].
动物实验	Athymic Nude-Foxn1nu/nu mice were used in the present study. They were housed at 22°C at a constant light-dark cycle (12-h light, 12-h dark) and had free access to water and rodent chow (4-5% fat, 21% protein). Twelve weeks old male mice (n = 14) were anesthetized with Isofluran and 5 × 10^6 MES-SA cells were injected subcutaneously into the right flank of the animal. Mice from a control group received placebo containing 300 μl of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice received vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat were administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size (w2 × l × 0.52; measured by caliper) were estimated twice a week. All mice were treated for 21 days and afterward sacrificed by cervical dislocation. Each tumor was isolated as a whole and different tumor parameters (weight, volume, size, and macroscopic appearance) were determined. Finally, tumor slices were cryopreserved and formalin fixed (4%) for further analyses [1].
体外活性	方法：滑膜肉瘤细胞 SW-982 和软骨肉瘤细胞 SW-1353 用 Vorinostat (0.5-15 μM) 处理 48 h，使用 MST assay 检测细胞活力。结果：Vorinostat 以剂量依赖的方式抑制 SW-982 和 SW-1353 细胞增殖，IC50 分别为 8.6 μM 和 2.0 μM。[1] 方法：子宫肉瘤细胞 MES-SA 用 Vorinostat (3 μM) 处理 24-72 h，使用 Western Blot 方法检测靶点蛋白表达水平。结果：在整个处理期间，HDAC1 的表达没有差异。HDAC2、3 和 7 显示出 Vorinostat 对表达的显著抑制。[2]
体内活性	方法：为检测体内抗肿瘤活性，将 Vorinostat (50 mg/kg in HOP-β-CD) 腹腔注射给携带子宫肉瘤 MES-SA 的 Nude-Foxn1nu/nu 小鼠，每周五次，持续二十一天。结果：与安慰剂组相比，Vorinostat 治疗组观察到肿瘤生长减少了 50% 以上。[1] 方法：为研究在真性红细胞增多症 (PV) 动物模型中的作用，将 Vorinostat (200 mg/kg in 50% PEG-400) 腹腔注射给 MxCre;Jak2V617F/+ 小鼠，每周五次，持续两周。结果：Vorinostat 治疗使 Jak2V617F 敲除小鼠的外周血计数正常化，并显著减少脾肿大。Vorinostat 可能对 PV 和其他 JAK2V617F 相关的骨髓增生性肿瘤具有治疗潜力。[3]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 12.5 mg/mL (47.29 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Ethanol : 2 mg/mL (7.6 mM) DMSO : 125 mg/mL (472.90 mM), Sonication is recommended.
关键字	Autophagy \| Apoptosis \| Filovirus \| Histone deacetylases \| Human papillomavirus \| inhibit \| HDAC \| Inhibitor \| Mitophagy \| Vorinostat \| MK 0683 \| Mitochondrial Autophagy \| HPV \| MK-0683
相关产品	Guanidine hydrochloride \| Naringin \| Valproic Acid \| L-Glutamic acid \| Gefitinib \| Hydroxychloroquine \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| L-Ascorbic acid \| Paeonol \| Sodium 4-phenylbutyrate \| Phenytoin sodium
相关库	抑制剂库 \| 经典已知活性库 \| 抗癌活性化合物库 \| 抗癌上市药物库 \| 抗衰老化合物库 \| FDA 上市药物库 \| 抗病毒库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

伏立诺他|||suberoylanilide hydroxamic acid|||SAHA|||MK0683|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子